Modeling Resistance to Pathway-targeted Therapy in Ovarian Cancer

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2005 Jun 23

PMID 15970711

Citations 14

Authors

Deyin Xing

Sandra Orsulic

Affiliations

Soon will be listed here.

Abstract

A detailed understanding of the biochemical pathways that are responsible for cancer initiation and maintenance is critical to designing targeted cancer therapy. Although we have accumulated knowledge about individual molecular changes that underlie cancer development, we are still learning how multiple biochemical pathways cooperate in cancer. This cooperation and cross-talk between redundant biochemical pathways appear to be the main reasons for the failure of therapeutic agents that are designed to interfere with a specific molecular target. In order to simulate the cooperation of several biochemical pathways in cancer development, we have engineered mouse ovarian cancer cell lines and tumors with different combinations of defined genetic alterations. We have used this system to determine the functional contributions of individual pathways that are necessary for cell proliferation and tumor maintenance, as well as to test the molecular mechanisms of tumor resistance to pathway-targeted therapy.

Citing Articles

Impact of Combination Therapy with Chemical Drugs and Megavoltage X-ray Exposure on Breast Cancer Stem Cells' Viability and Proliferation of MCF-7 and MDA-MB-231 Cell Lines.

Banisharif Dehkordi F, Ghatrehsamani M, Abdolvand M, Soltani A, Masoumi S Curr Pharm Des. 2024; 30(17):1341-1353.

PMID: 38676476 DOI: 10.2174/0113816128287325240329085055.

Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings.

Tossetta G Int J Mol Sci. 2022; 23(21).

PMID: 36361682 PMC: 9654053. DOI: 10.3390/ijms232112893.

FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer.

Recouvreux M, Miao J, Gozo M, Wu J, Walts A, Karlan B Cancers (Basel). 2022; 14(19).

PMID: 36230774 PMC: 9564305. DOI: 10.3390/cancers14194851.

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy.

Romagnoli A, Maracci C, DAgostino M, La Teana A, Di Marino D Cancer Drug Resist. 2022; 4(3):596-606.

PMID: 35582305 PMC: 9094073. DOI: 10.20517/cdr.2021.20.

Molecular events in the pathogenesis of vulvar squamous cell carcinoma.

Xing D, Fadare O Semin Diagn Pathol. 2020; 38(1):50-61.

PMID: 33032902 PMC: 7749059. DOI: 10.1053/j.semdp.2020.09.010.

References

Grunwald V, deGraffenried L, Russel D, Friedrichs W, Ray R, Hidalgo M . Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002; 62(21):6141-5. View

Orsulic S . An RCAS-TVA-based approach to designer mouse models. Mamm Genome. 2002; 13(10):543-7. DOI: 10.1007/s00335-002-4003-4. View

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

Coleman M, Marshall C, Olson M . Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J. 2003; 22(9):2036-46. PMC: 156064. DOI: 10.1093/emboj/cdg189. View

Huang S, Houghton P . Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003; 3(4):371-7. DOI: 10.1016/s1471-4892(03)00071-7. View

Rajasekhar V, Viale A, Socci N, Wiedmann M, Hu X, Holland E . Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell. 2003; 12(4):889-901. DOI: 10.1016/s1097-2765(03)00395-2. View

Weiss R . p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell. 2004; 4(6):425-9. DOI: 10.1016/s1535-6108(03)00308-8. View

Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R . Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004; 64(1):252-61. DOI: 10.1158/0008-5472.can-3554-2. View

Wendel H, de Stanchina E, Fridman J, Malina A, Ray S, Kogan S . Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004; 428(6980):332-7. DOI: 10.1038/nature02369. View

10.

Facchinetti M, De Siervi A, Toskos D, Senderowicz A . UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. Cancer Res. 2004; 64(10):3629-37. DOI: 10.1158/0008-5472.CAN-03-3741. View

11.

Majumder P, Febbo P, Bikoff R, Berger R, Xue Q, McMahon L . mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10(6):594-601. DOI: 10.1038/nm1052. View

12.

Altomare D, Wang H, Skele K, De Rienzo A, Klein-Szanto A, Godwin A . AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004; 23(34):5853-7. DOI: 10.1038/sj.onc.1207721. View

13.

Lloyd A, Obermuller F, Staddon S, Barth C, McMahon M, Land H . Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 1997; 11(5):663-77. DOI: 10.1101/gad.11.5.663. View

14.

Sewing A, Wiseman B, Lloyd A, Land H . High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol. 1997; 17(9):5588-97. PMC: 232407. DOI: 10.1128/MCB.17.9.5588. View

15.

Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M . Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 1997; 17(9):5598-611. PMC: 232408. DOI: 10.1128/MCB.17.9.5598. View

16.

Brunn G, Fadden P, Haystead T, Lawrence Jr J . The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. J Biol Chem. 1998; 272(51):32547-50. DOI: 10.1074/jbc.272.51.32547. View

17.

Olson M, PATERSON H, Marshall C . Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature. 1998; 394(6690):295-9. DOI: 10.1038/28425. View

18.

Hosoi H, Dilling M, Shikata T, Liu L, Shu L, Ashmun R . Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999; 59(4):886-94. View

19.

Louro I, Gosnell H, Brindley B, Bucy R, Ruppert J . The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Cell Growth Differ. 1999; 10(7):503-16. View

20.

Uhrbom L, Nerio E, Holland E . Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med. 2004; 10(11):1257-60. DOI: 10.1038/nm1120. View